• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SHARED：一项旨在破解丙型肝炎耐药性的国际合作。

SHARED: An International Collaboration to Unravel Hepatitis C Resistance.

机构信息

British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

出版信息

Viruses. 2021 Aug 10;13(8):1580. doi: 10.3390/v13081580.

DOI:10.3390/v13081580
PMID:34452444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8402898/
Abstract

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...].

摘要

直接作用抗病毒药物（DAAs）的出现改变了丙型肝炎的治疗格局[... ]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7a/8402898/678c7b5db714/viruses-13-01580-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7a/8402898/678c7b5db714/viruses-13-01580-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a7a/8402898/678c7b5db714/viruses-13-01580-g001.jpg

相似文献

1
SHARED: An International Collaboration to Unravel Hepatitis C Resistance.SHARED：一项旨在破解丙型肝炎耐药性的国际合作。
Viruses. 2021 Aug 10;13(8):1580. doi: 10.3390/v13081580.
2
Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.直接作用抗病毒药物与丙型肝炎病毒耐药性概述
Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1.
3
[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].[直接作用抗病毒药物治疗丙型肝炎中耐药相关突变的临床意义]
Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):170-174. doi: 10.3760/cma.j.issn.1007-3418.2017.03.003.
4
[Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].[直接作用抗病毒药物治疗丙型肝炎病毒耐药性的反应预测因素]
Nihon Rinsho. 2015 Dec;73 Suppl 9:189-92.
5
[A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].[临床实践中的一项新挑战：丙型肝炎治疗中对直接作用抗病毒药物的耐药性]
Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):165-9. doi: 10.3760/cma.j.issn.1007-3418.2016.03.002.
6
Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.作为耐药性产生的关键参数，丙型肝炎中的遗传屏障和变异适应性
Drug Discov Today Technol. 2014 Mar;11:19-25. doi: 10.1016/j.ddtec.2013.12.003.
7
Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.直接作用抗病毒药物治疗失败患者的再治疗：重点关注丙型肝炎病毒 1b 型。
World J Gastroenterol. 2017 Dec 14;23(46):8120-8127. doi: 10.3748/wjg.v23.i46.8120.
8
Clinical relevance of HCV antiviral drug resistance.HCV 抗病毒药物耐药性的临床意义。
Curr Opin Virol. 2012 Oct;2(5):651-5. doi: 10.1016/j.coviro.2012.08.008. Epub 2012 Sep 21.
9
Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals.撒哈拉以南非洲地区使用直接作用抗病毒药物治疗 1 至 5 型丙型肝炎。
Am J Trop Med Hyg. 2020 Nov;103(5):2083-2084. doi: 10.4269/ajtmh.20-0367.
10
Hepatitis C Virus: Viral Quasispecies and Genotypes.丙型肝炎病毒：病毒准种和基因型。
Int J Mol Sci. 2017 Dec 22;19(1):23. doi: 10.3390/ijms19010023.

引用本文的文献

1
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.慢性丙型肝炎感染患者以及初次或再次使用泛基因型直接抗病毒药物治疗后病毒学失败患者中耐药相关替代位点的流行率：一项系统评价和荟萃分析
Clin Infect Dis. 2024 Dec 17;79(6):1437-1446. doi: 10.1093/cid/ciae431.
2
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.一组有欧洲直接抗病毒药物治疗经验患者中的罕见丙肝病毒亚型及再治疗结果
JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul.
3

本文引用的文献

1
Treatment failure with DAA therapy: Importance of resistance.直接抗病毒药物（DAA）治疗失败：耐药性的重要性
J Hepatol. 2021 Jun;74(6):1472-1482. doi: 10.1016/j.jhep.2021.03.004. Epub 2021 Mar 12.
2
Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study.高收入国家不常见的丙型肝炎基因型的直接抗病毒治疗：一项荷兰全国队列研究。
Open Forum Infect Dis. 2021 Jan 6;8(2):ofab006. doi: 10.1093/ofid/ofab006. eCollection 2021 Feb.
3
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.
丙型肝炎病毒的当代见解：全面综述
Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035.
4
Hepatitis C: recent advances and practical management.丙型肝炎：最新进展与实际管理
Frontline Gastroenterol. 2023 Jun 13;14(5):415-421. doi: 10.1136/flgastro-2022-102373. eCollection 2023.
5
Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.接受直接抗病毒药物治疗失败的丙型肝炎病毒基因3型（HCV GT3）患者中与耐药相关替代位点的出现与持续存在
Front Pharmacol. 2022 Apr 27;13:894460. doi: 10.3389/fphar.2022.894460. eCollection 2022.
6
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.在使用直接作用抗病毒药物十年后的国际队列中丙型肝炎病毒耐药性特征
JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May.
7
Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay.验证一种基因型独立的丙型肝炎病毒全基因组测序检测方法。
Viruses. 2021 Aug 30;13(9):1721. doi: 10.3390/v13091721.
NS5A 抑制剂对撒哈拉以南非洲和东南亚常见的不常见且可能难以治疗的 HCV 亚型的疗效。
J Hepatol. 2020 Oct;73(4):794-799. doi: 10.1016/j.jhep.2020.05.029. Epub 2020 May 26.
4
Transmission of NS5A-Inhibitor Resistance-Associated Substitutions Among Men Who Have Sex With Men Recently Infected with Hepatitis C Virus Genotype 1a.近期感染 HCV 基因 1a 的男男性行为者中 NS5A 抑制剂耐药相关替换的传播。
Clin Infect Dis. 2020 Nov 5;71(8):e215-e217. doi: 10.1093/cid/ciaa145.
5
DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?非洲“不常见”丙型肝炎病毒（HCV）亚型患者中直接抗病毒药物（DAA）治疗失败：嘿！你难道不知道还有另一个世界吗？
J Hepatol. 2019 Dec;71(6):1070-1072. doi: 10.1016/j.jhep.2019.09.021. Epub 2019 Oct 21.
6
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.非洲非典型 1 型基因型患者的 SVR 率不理想：对全球消除丙型肝炎的影响。
J Hepatol. 2019 Dec;71(6):1099-1105. doi: 10.1016/j.jhep.2019.07.025. Epub 2019 Aug 7.
7
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.索磷布韦/维帕他韦治疗亚洲慢性丙型肝炎病毒感染：一项单臂、开放标签、3 期临床试验。
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1. Epub 2018 Dec 14.
8
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.卢旺达采用 ledipasvir-索非布韦（SHARED）治疗慢性丙型肝炎病毒感染：一项单臂试验。
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. doi: 10.1016/S2468-1253(18)30382-0. Epub 2018 Dec 11.
9
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C.需要一个欧洲丙型肝炎项目来在现实生活中监测对直接作用抗病毒药物的耐药性，以消除丙型肝炎。
J Virus Erad. 2018 Jul 1;4(3):179-181. doi: 10.1016/S2055-6640(20)30267-3.
10
Nextstrain: real-time tracking of pathogen evolution.Nextstrain：实时追踪病原体进化。
Bioinformatics. 2018 Dec 1;34(23):4121-4123. doi: 10.1093/bioinformatics/bty407.